HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase

(2010) E Di Gennaro et al.   BRITISH JOURNAL OF CANCER

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed

(2010) Elena Di Gennaro et al.   CANCER BIOLOGY & THERAPY

ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination

(2010) Corina Marx et al.   CANCER RESEARCH

New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors

(2010) L. F. Chen et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

(2010) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma

(2010) A. Iglesias-Linares et al.   ORAL ONCOLOGY

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)

(2009) S. E. Witta et al.   ANNALS OF ONCOLOGY

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma

(2009) J. J.-C. Sheu et al.   CANCER RESEARCH

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

(2009) X. Huang et al.   CANCER RESEARCH

Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines

(2009) Y. Haddad et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines

(2009) Michael B Prystowsky et al.   JOURNAL OF PATHOLOGY

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines

(2009) Wei Zhang et al.   Journal of Thoracic Oncology

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

The morphological and molecular features of the epithelial-to-mesenchymal transition

(2009) Gema Moreno-Bueno et al.   Nature Protocols

Molecular therapy in head and neck oncology

(2009) Jacques Bernier et al.   Nature Reviews Clinical Oncology

The ERBB3 receptor in cancer and cancer gene therapy

(2008) G Sithanandam et al.   CANCER GENE THERAPY

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6

(2008) G. K. Scott et al.   MOLECULAR CANCER RESEARCH

Recent Advances in Head and Neck Cancer

(2008) Robert I. Haddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients

(2008) Hao-Hueng Chang et al.   ORAL ONCOLOGY

Epithelial–mesenchymal transition and the invasive potential of tumors

(2008) Nancy Gavert et al.   TRENDS IN MOLECULAR MEDICINE